SBIR/STTR Research Award

CELLULAR PARAMETERS OF DRUG SENSITIVITY IN HUMAN TUMORS IN VITRO

Award identifier 08b4be7f71242df6db5398adb45462642cb6d30d7d10fe4f3f130b48822f72c9Awarding agency Department of Health and Human Services

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

1988

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
ANTICANCER, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

AN IMPORTANT NEED IN CANCER CHEMOTHERAPY IS A HIGHLY PREDICTIVE IN VITRO CHEMOSENSITIVITY ASSAY. A MAJOR IMPEDIMENT TO THE DEVELOPMENT OF SUCH A TEST HAS BEEN THE LACK OF A SUITABLE SYSTEM FOR CULTURING HUMAN TUMORS IN VITRO SO THAT THEY REPRESENT TUMORS IN THE IN VIVO STATE. TO OVERCOME THIS PROBLEM, ANTICANCER, INC. HAS RECENTLY DEVELOPED A TUMOR CULTURE SYSTEM FOR THE IN VITRO GROWTH OF DIVERSE HUMAN TUMORS IN AN IN VIVO-LIKE WAY. THIS SYSTEM ALLOWS OVER 75% OF EXPLANTED TUMORS TO BE GROWN FOR PERIODS OF TIME THAT AVERAGE OVER 90 DAYS. THE TUMORS ARE EXPLANTEDON GELS DERIVED FROM PIGSKIN RICH IN EXTRACELLULAR-MATRIX BASEMENT-MEMBRANE COMPONENTS SUCH AS VARIOUS COLLAGENS AND LAMININ. THIS TUMOR CULTURE SYSTEM ALLOWS THE READY MEASUREMENT OF DNA AND PROTEIN SYNTHESIS IN INDIVIDUAL CELLSWITHIN TUMORS BY AUTORADIOGRAPHIC TECHNIQUES. THIS RESEARCHWILL UTILIZE THIS METHOD OF HUMAN TUMOR CULTURE TO DETERMINETHE CRITICAL PARAMETERS FOR IN VITRO DRUG SENSITIVITY TESTING WITH THE EVENTUAL GOAL OF DETERMINING WHICH PARAMETERS ARE THE MOST PREDICTIVE OF THE IN VIVO RESPONSE OF TUMORS TO DRUGS. IN THIS LIGHT, CHEMOTHERAPEUTIC DRUGS WILL BE TESTED FOR THEIR EFFECT ON DNA SYNTHESIS, PROTEIN SYNTHESIS, AND CELL VIABILITY STAINING IN A QUANTITATIVE MANNER. IN CONCERT WITH THE ABOVE EXPERIMENTS, ANTIBODIES WILL BE USED TO DETERMINE SPECIFIC CELL-TYPE MARKERS WITHIN THE VARIOUS TYPES OF HUMAN TUMOR CULTURES GROWING IN VITRO IN ORDER TO IDENTIFY THE ESSENTIAL NATURE OF CELLS WITHIN TUMORS. THIS IS ESPECIALLY CRITICAL FOR MEASURING DRUG SENSITIVITIES. TUMORS OF THE BREAST, LUNG, AND, COLON WILL BE EMPHASIZED. PATIENT RESPONSE DATA WILL BE OBTAINED AND CORRELATED TO IN VITRO CHEMOSENSITIVITIES TO DETERMINE THE MOST PREDICTIVE IN VITRO PARAMETERS. THE EXPERIMENTS PROPOSED HERE SHOULD ALLOW A MAJOR ADVANCE TOWARD THE GOAL OF A COMMERCIAL DRUG SENSITIVITY TEST.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.